The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis
Abstract The SEPT9 gene methylation assay is the first FDA-approved blood assay for colorectal cancer (CRC) screening. Fecal immunochemical test (FIT), FIT-DNA test and CEA assay are also in vitro diagnostic (IVD) tests used in CRC screening. This meta-analysis aims to review the SEPT9 assay perform...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2017-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-017-03321-8 |
| _version_ | 1819036324344102912 |
|---|---|
| author | Lele Song Jia Jia Xiumei Peng Wenhua Xiao Yuemin Li |
| author_facet | Lele Song Jia Jia Xiumei Peng Wenhua Xiao Yuemin Li |
| author_sort | Lele Song |
| collection | DOAJ |
| description | Abstract The SEPT9 gene methylation assay is the first FDA-approved blood assay for colorectal cancer (CRC) screening. Fecal immunochemical test (FIT), FIT-DNA test and CEA assay are also in vitro diagnostic (IVD) tests used in CRC screening. This meta-analysis aims to review the SEPT9 assay performance and compare it with other IVD CRC screening tests. By searching the Ovid MEDLINE, EMBASE, CBMdisc and CJFD database, 25 out of 180 studies were identified to report the SEPT9 assay performance. 2613 CRC cases and 6030 controls were included, and sensitivity and specificity were used to evaluate its performance at various algorithms. 1/3 algorithm exhibited the best sensitivity while 2/3 and 1/1 algorithm exhibited the best balance between sensitivity and specificity. The performance of the blood SEPT9 assay is superior to that of the serum protein markers and the FIT test in symptomatic population, while appeared to be less potent than FIT and FIT-DNA tests in asymptomatic population. In conclusion, 1/3 algorithm is recommended for CRC screening, and 2/3 or 1/1 algorithms are suitable for early detection for diagnostic purpose. The SEPT9 assay exhibited better performance in symptomatic population than in asymptomatic population. |
| first_indexed | 2024-12-21T08:03:43Z |
| format | Article |
| id | doaj.art-85bc8435fe9c4196991cda2e5dc58d96 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-21T08:03:43Z |
| publishDate | 2017-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-85bc8435fe9c4196991cda2e5dc58d962022-12-21T19:10:51ZengNature PortfolioScientific Reports2045-23222017-06-017111210.1038/s41598-017-03321-8The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysisLele Song0Jia Jia1Xiumei Peng2Wenhua Xiao3Yuemin Li4Department of Radiotherapy, The Chinese PLA 309th HospitalDepartment of Radiotherapy, The Chinese PLA 309th HospitalMedical School of Chinese PLA and Chinese PLA General HospitalDepartment of Oncology, First Affiliated Hospital of Chinese PLA General HospitalDepartment of Radiotherapy, The Chinese PLA 309th HospitalAbstract The SEPT9 gene methylation assay is the first FDA-approved blood assay for colorectal cancer (CRC) screening. Fecal immunochemical test (FIT), FIT-DNA test and CEA assay are also in vitro diagnostic (IVD) tests used in CRC screening. This meta-analysis aims to review the SEPT9 assay performance and compare it with other IVD CRC screening tests. By searching the Ovid MEDLINE, EMBASE, CBMdisc and CJFD database, 25 out of 180 studies were identified to report the SEPT9 assay performance. 2613 CRC cases and 6030 controls were included, and sensitivity and specificity were used to evaluate its performance at various algorithms. 1/3 algorithm exhibited the best sensitivity while 2/3 and 1/1 algorithm exhibited the best balance between sensitivity and specificity. The performance of the blood SEPT9 assay is superior to that of the serum protein markers and the FIT test in symptomatic population, while appeared to be less potent than FIT and FIT-DNA tests in asymptomatic population. In conclusion, 1/3 algorithm is recommended for CRC screening, and 2/3 or 1/1 algorithms are suitable for early detection for diagnostic purpose. The SEPT9 assay exhibited better performance in symptomatic population than in asymptomatic population.https://doi.org/10.1038/s41598-017-03321-8 |
| spellingShingle | Lele Song Jia Jia Xiumei Peng Wenhua Xiao Yuemin Li The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis Scientific Reports |
| title | The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis |
| title_full | The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis |
| title_fullStr | The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis |
| title_full_unstemmed | The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis |
| title_short | The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis |
| title_sort | performance of the sept9 gene methylation assay and a comparison with other crc screening tests a meta analysis |
| url | https://doi.org/10.1038/s41598-017-03321-8 |
| work_keys_str_mv | AT lelesong theperformanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT jiajia theperformanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT xiumeipeng theperformanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT wenhuaxiao theperformanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT yueminli theperformanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT lelesong performanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT jiajia performanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT xiumeipeng performanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT wenhuaxiao performanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis AT yueminli performanceofthesept9genemethylationassayandacomparisonwithothercrcscreeningtestsametaanalysis |